Marisol del V Cano and Peter L. Gehlbach

Copyright © 2008 Marisol del V Cano and Peter L. Gehlbach. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. R. Klein, B. E. Klein, and K. L. Linton, “Prevalence of age-related maculopathy. The Beaver Dam Eye Study,” Ophthalmology, vol. 99, no. 6, pp. 933–943, 1992.
2. F. Kinose, G. Roscilli, S. Lamartina, et al., “Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor,” Molecular Vision, vol. 11, pp. 366–373, 2005.
3. B. Muñoz, S. K. West, G. S. Rubin, et al., “Causes of blindness and visual impairment in a population of older Americans. The Salisbury Eye Evaluation Study,” Archives of Ophthalmology, vol. 118, no. 6, pp. 819–825, 2000.
4. R. Klein, B. E. Klein, S. C. Jensen, and S. M. Meuer, “The five-year incidence and progression of age-related maculopathy. The Beaver Dam Eye Study,” Ophthalmology, vol. 104, no. 1, pp. 7–21, 1997.
5. H. M. Leibowitz, D. E. Krueger, L. R. Maunder, et al., “The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973–1975,” Survey of Ophthalmology, vol. 24, supplement 1, pp. 335–610, 1980.
6. E. W. M. Ng, D. T. Shima, P. Calias, E. T. Cunningham, Jr., D. R. Guyer, and A. P. Adamis, “Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease,” Nature Reviews Drug Discovery, vol. 5, no. 2, pp. 123–132, 2006.
7. J. S. Heier, A. N. Antoszyk, P. R. Pavan, et al., “Ranibizumab for treatment of neovascular age-related macular degeneration. A phase I/II multicenter, controlled, multidose study,” Ophthalmology, vol. 113, no. 4, pp. 633–642, 2006.
8. S. Michels and P. J. Rosenfeld, “Treatment of neovascular age-related macular degeneration with Ranibizumab/${\text{Lucentis}}^{\text{TM}}$,” Klinische Monatsblätter für Augenheilkunde, vol. 222, no. 6, pp. 480–484, 2005.
9. S. Michels, P. J. Rosenfeld, C. A. Puliafito, E. N. Marcus, and A. S. Venkatraman, “Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study,” Ophthalmology, vol. 112, no. 6, pp. 1035–1047, 2005.
10. R. L. Avery, D. J. Pieramici, M. D. Rabena, A. A. Castellarin, M. A. Nasir, and M. J. Giust, “Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration,” Ophthalmology, vol. 113, no. 3, pp. 363–372, 2006.
11. C. Bonne, “PPAR $\gamma$: a novel pharmacological target against retinal and choroidal neovascularization,” Journal Français d'Ophtalmologie, vol. 28, no. 3, pp. 326–330, 2005.
12. F. Chang, L. A. Jaber, H. D. Berlie, and M. B. O'Connell, “Evolution of peroxisome proliferator-activated receptor agonists,” The Annals of Pharmacotherapy, vol. 41, no. 6, pp. 973–983, 2007.
13. O. Braissant, F. Foufelle, C. Scotto, M. Dauca, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-$\alpha$, -$\beta$, and -$\gamma$ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996.
14. D. Auboeuf, J. Rieusset, L. Fajas, et al., “Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-$\alpha$ in humans: no alteration in adipose tissue of obese and NIDDM patients,” Diabetes, vol. 46, no. 8, pp. 1319–1327, 1997.
15. T. Lemberger, O. Braissant, C. Juge-Aubry, et al., “PPAR tissue distribution and interactions with other hormone-signaling pathways,” Annals of the New York Academy of Sciences, vol. 804, pp. 231–251, 1996.
16. B. Staels, W. Koenig, A. Habib, et al., “Activation of human aortic smooth-muscle cells is inhibited by PPAR$\alpha$ but not by PPAR$\gamma$ activators,” Nature, vol. 393, no. 6687, pp. 790–793, 1998.
17. I. Inoue, K. Shino, S. Noji, T. Awata, and S. Katayama, “Expression of peroxisome proliferator-activated receptor $\alpha$ (PPAR$\alpha$) in primary cultures of human vascular endothelial cells,” Biochemical and Biophysical Research Communications, vol. 246, no. 2, pp. 370–374, 1998.
18. G. Chinetti, S. Griglio, M. Antonucci, et al., “Activation of proliferator-activated receptors $\alpha$ and $\gamma$ induces apoptosis of human monocyte-derived macrophages,” Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998.
19. S. W. Cousins, D. G. Espinosa-Heidmann, and K. G. Csaky, “Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization?,” Archives of Ophthalmology, vol. 122, no. 7, pp. 1013–1018, 2004.
20. A. Chawla, E. J. Schwarz, D. D. Dimaculangan, and M. A. Lazar, “Peroxisome proliferator-activated receptor (PPAR) $\gamma$: adipose-predominant expression and induction early in adipocyte differentiation,” Endocrinology, vol. 135, no. 2, pp. 798–800, 1994.
21. J. Auwerx, G. Martin, M. Guerre-Millo, and B. Staels, “Transcription, adipocyte differentiation, and obesity,” Journal of Molecular Medicine, vol. 74, no. 7, pp. 347–352, 1996.
22. R. Komers and A. Vrana, “Thiazolidinediones—tools for the research of metabolic syndrome X,” Physiological Research, vol. 47, no. 4, pp. 215–225, 1998.
23. H. Itoh, K. Doi, T. Tanaka, et al., “Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor $\gamma$,” Clinical and Experimental Pharmacology and Physiology, vol. 26, no. 7, pp. 558–560, 1999.
24. J. Plutzky, “Peroxisome proliferator-activated receptors in endothelial cell biology,” Current Opinion in Lipidology, vol. 12, no. 5, pp. 511–518, 2001.
25. C. Giaginis, A. Margeli, and S. Theocharis, “Peroxisome proliferator-activated receptor-$\gamma$ ligands as investigational modulators of angiogenesis,” Expert Opinion on Investigational Drugs, vol. 16, no. 10, pp. 1561–1572, 2007.
26. M. Meissner, M. Stein, C. Urbich, et al., “PPAR$\alpha$ activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation,” Circulation Research, vol. 94, no. 3, pp. 324–332, 2004.
27. J. Varet, L. Vincent, P. Mirshahi, et al., “Fenofibrate inhibits angiogenesis in vitro and in vivo,” Cellular and Molecular Life Sciences, vol. 60, no. 4, pp. 810–819, 2003.
28. X. R. Chen, V. C. Besson, B. Palmier, Y. Garcia, M. Plotkine, and C. Marchand-Leroux, “Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR $\alpha$ agonist, in traumatic brain injury,” Journal of Neurotrauma, vol. 24, no. 7, pp. 1119–1131, 2007.
29. R. Bordet, T. Ouk, O. Petrault, et al., “PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases,” Biochemical Society Transactions, vol. 34, part 6, pp. 1341–1346, 2006.
30. M. Arca, S. Natoli, F. Micheletta, et al., “Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy,” Free Radical Biology and Medicine, vol. 42, no. 5, pp. 698–705, 2007.
31. S. H. Han, M. J. Quon, and K. K. Koh, “Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-$\alpha$ activators,” Hypertension, vol. 46, no. 5, pp. 1086–1092, 2005.
32. Z. Israelian-Konaraki and P. D. Reaven, “Peroxisome proliferator-activated receptor-$\alpha$ and atherosclerosis: from basic mechanisms to clinical implications,” Cardiology, vol. 103, no. 1, pp. 1–9, 2005.
33. N. Marx, U. Schönbeck, M. A. Lazar, P. Libby, and J. Plutzky, “Peroxisome proliferator-activated receptor $\gamma$ activators inhibit gene expression and migration in human vascular smooth muscle cells,” Circulation Research, vol. 83, no. 11, pp. 1097–1103, 1998.
34. M. Iglarz, R. M. Touyz, F. Amiri, M.-F. Lavoie, Q. N. Diep, and E. L. Schiffrin, “Effect of peroxisome proliferator-activated receptor-$\alpha$ and -$\gamma$ activators on vascular remodeling in endothelin-dependent hypertension,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 45–51, 2003.
35. P. Delerive, J. C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors in inflammation control,” Journal of Endocrinology, vol. 169, no. 3, pp. 453–459, 2001.
36. N. Ferrara and H.-P. Gerber, “The role of vascular endothelial growth factor in angiogenesis,” Acta Haematologica, vol. 106, no. 4, pp. 148–156, 2001.
37. A. D. Kulkarni and B. D. Kuppermann, “Wet age-related macular degeneration,” Advanced Drug Delivery Reviews, vol. 57, no. 14, pp. 1994–2009, 2005.
38. N. Ferrara, “The role of VEGF in the regulation of physiological and pathological angiogenesis,” EXS, no. 94, pp. 209–231, 2005.
39. A. Kvanta, P. V. Algvere, L. Berglin, and S. Seregard, “Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor,” Investigative Ophthalmology and Visual Science, vol. 37, no. 9, pp. 1929–1934, 1996.
40. P. F. Lopez, B. D. Sippy, H. M. Lambert, A. B. Thach, and D. R. Hinton, “Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes,” Investigative Ophthalmology and Visual Science, vol. 37, no. 5, pp. 855–868, 1996.
41. M. Kliffen, H. S. Sharma, C. M. Mooy, S. Kerkvliet, and P. T. de Jong, “Increased expression of angiogenic growth factors in age-related maculopathy,” British Journal of Ophthalmology, vol. 81, no. 2, pp. 154–162, 1997.
42. J. A. Wells, R. Murthy, R. Chibber, et al., “Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation,” British Journal of Ophthalmology, vol. 80, no. 4, pp. 363–366, 1996.
43. V. Simorre-Pinatel, M. Guerrin, P. Chollet, et al., “Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway,” Investigative Ophthalmology and Visual Science, vol. 35, no. 9, pp. 3393–3400, 1994.
44. L. P. Aiello, J. M. Northrup, B. A. Keyt, H. Takagi, and M. A. Iwamoto, “Hypoxic regulation of vascular endothelial growth factor in retinal cells,” Archives of Ophthalmology, vol. 113, no. 12, pp. 1538–1544, 1995.
45. A. P. Adamis, D. T. Shima, K. T. Yeo, et al., “Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells,” Biochemical and Biophysical Research Communications, vol. 193, no. 2, pp. 631–638, 1993.
46. E. A. Pierce, R. L. Avery, E. D. Foley, L. P. Aiello, and L. E. H. Smith, “Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 3, pp. 905–909, 1995.
47. Y. Yokoyama, B. Xin, T. Shigeto, et al., “Clofibric acid, a peroxisome proliferator-activated receptor $\alpha$ ligand, inhibits growth of human ovarian cancer,” Molecular Cancer Therapeutics, vol. 6, no. 4, pp. 1379–1386, 2007.
48. R. Pola, E. Gaetani, A. Flex, et al., “Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors,” Journal of Molecular and Cellular Cardiology, vol. 36, no. 3, pp. 363–370, 2004.
49. T. Murata, S. He, M. Hangai, et al., “Peroxisome proliferator-activated receptor-$\gamma$ ligands inhibit choroidal neovascularization,” Investigative Ophthalmology and Visual Science, vol. 41, no. 8, pp. 2309–2317, 2000.
50. F. Zandbergen and J. Plutzky, “PPAR$\alpha$ in atherosclerosis and inflammation,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 972–982, 2007.
51. R. Hogg and U. Chakravarthy, “AMD and micronutrient antioxidants,” Current Eye Research, vol. 29, no. 6, pp. 387–401, 2004.